Apogee Therapeutics (NASDAQ:APGE – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Citigroup in a research note issued on Tuesday,Benzinga reports. They presently have a $135.00 price objective on the stock, up from their prior price objective of $125.00. Citigroup’s price target suggests a potential upside of 1.69% from […]

Apogee Therapeutics (NASDAQ:APGE – Get Free Report)‘s stock had its “hold” rating restated by equities research analysts at Canaccord Genuity Group in a report released on Monday,Benzinga reports. They presently have a $135.11 price target on the stock, up from their prior price target of $130.00. Canaccord Genuity Group’s price objective would suggest a potential […]

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Canaccord Genuity Group in a report released on Tuesday,Benzinga reports. They currently have a $49.00 price objective on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 258.84% from the stock’s current price. Other […]

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Wedbush in a note issued to investors on Monday,Benzinga reports. They presently have a $12.00 target price on the stock. Wedbush’s price target would suggest a potential downside of 11.03% from the company’s previous close. Several other research firms […]